This newsletter presents you the following key sessions:
1. Podcast with Prof. Hatem A. Azim about fertility preservation and assisted reproductive technologies in
breast cancer patients interrupting endocrine therapy to attempt pregnancy
2. Adding abemaciclib to first line endocrine therapy prolongs the median OS with more than a year in patients
with HR+/HER2- advanced breast cancer
3. Pembrolizumab plus neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery as a
standard of care for patients with early-stage TNBC
4. T-DM1 is less effective than trastuzumab-pertuzumab-docetaxel in older patients with HER2+ metastatic
breast cancer, but comes with a lower rate of grade ≥3 adverse events
5. Safe omission of post-surgery radiotherapy for patients with low DCIS score